PMC:7200337 / 94044-94678
Annnotations
2_test
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
32505227-21047436-46575418 | 287-291 | 21047436 | denotes | 2010 |
32505227-16318725-46575419 | 304-308 | 16318725 | denotes | 2005 |
32505227-15220038-46575420 | 329-333 | 15220038 | denotes | 2004 |
32505227-14983044-46575421 | 366-370 | 14983044 | denotes | 2004 |
32505227-17620608-46575422 | 384-388 | 17620608 | denotes | 2007 |
32505227-26404138-46575423 | 418-422 | 26404138 | denotes | 2015 |
32505227-31130102-46575424 | 436-440 | 31130102 | denotes | 2019 |
32505227-25456101-46575425 | 455-459 | 25456101 | denotes | 2015 |
T46722 | 287-291 | 21047436 | denotes | 2010 |
T13757 | 304-308 | 16318725 | denotes | 2005 |
T32153 | 329-333 | 15220038 | denotes | 2004 |
T40642 | 366-370 | 14983044 | denotes | 2004 |
T65482 | 384-388 | 17620608 | denotes | 2007 |
T96040 | 418-422 | 26404138 | denotes | 2015 |
T25280 | 436-440 | 31130102 | denotes | 2019 |
T65647 | 455-459 | 25456101 | denotes | 2015 |
LitCovid-PD-FMA-UBERON
Id | Subject | Object | Predicate | Lexical cue | fma_id |
---|---|---|---|---|---|
T735 | 57-70 | Body_part | denotes | immune system | http://purl.org/sig/ont/fma/fma9825 |
LitCovid-PD-UBERON
Id | Subject | Object | Predicate | Lexical cue | uberon_id |
---|---|---|---|---|---|
T97 | 57-70 | Body_part | denotes | immune system | http://purl.obolibrary.org/obo/UBERON_0002405 |
LitCovid-PD-MONDO
Id | Subject | Object | Predicate | Lexical cue | mondo_id |
---|---|---|---|---|---|
T537 | 102-110 | Disease | denotes | SARS-CoV | http://purl.obolibrary.org/obo/MONDO_0005091 |
T538 | 263-271 | Disease | denotes | SARS-CoV | http://purl.obolibrary.org/obo/MONDO_0005091 |
T539 | 477-485 | Disease | denotes | SARS-CoV | http://purl.obolibrary.org/obo/MONDO_0005091 |
T540 | 566-576 | Disease | denotes | infections | http://purl.obolibrary.org/obo/MONDO_0005550 |
LitCovid-PD-CLO
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T969 | 46-47 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
T970 | 57-70 | http://purl.obolibrary.org/obo/UBERON_0002405 | denotes | immune system |
T971 | 170-171 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
T972 | 220-223 | http://purl.obolibrary.org/obo/CLO_0051582 | denotes | has |
T973 | 604-610 | http://purl.obolibrary.org/obo/NCBITaxon_33208 | denotes | animal |
LitCovid-PD-CHEBI
Id | Subject | Object | Predicate | Lexical cue | chebi_id |
---|---|---|---|---|---|
T312 | 293-295 | Chemical | denotes | Ho | http://purl.obolibrary.org/obo/CHEBI_49648 |
LitCovid-PubTator
Id | Subject | Object | Predicate | Lexical cue | tao:has_database_id |
---|---|---|---|---|---|
3092 | 239-241 | Gene | denotes | to | Gene:6999 |
3093 | 71-73 | Gene | denotes | to | Gene:6999 |
3094 | 35-37 | Gene | denotes | to | Gene:6999 |
3095 | 102-112 | Species | denotes | SARS-CoV-2 | Tax:2697049 |
3096 | 263-271 | Species | denotes | SARS-CoV | Tax:694009 |
3098 | 477-487 | Species | denotes | SARS-CoV-2 | Tax:2697049 |
3099 | 89-93 | Chemical | denotes | nAbs | |
3100 | 162-166 | Chemical | denotes | nAbs | |
3101 | 541-545 | Chemical | denotes | nAbs | |
3102 | 591-595 | Chemical | denotes | nAbs | |
3103 | 566-576 | Disease | denotes | infections | MESH:D007239 |
LitCovid-sentences
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T541 | 0-205 | Sentence | denotes | While vaccines are being developed to educate a person’s immune system to make their own nAbs against SARS-CoV-2, there is interest in using adoptive transfer of nAbs as a therapeutic approach (Figure 6D). |
T542 | 206-461 | Sentence | denotes | This strategy has already proven to be effective against SARS-CoV-1 (Cao et al., 2010, Ho et al., 2005, ter Meulen et al., 2004, Park et al., 2020, Sui et al., 2004, Zhu et al., 2007) and MERS-CoV (Forni et al., 2015, Jia et al., 2019, Ying et al., 2015). |
T543 | 462-634 | Sentence | denotes | In the case of SARS-CoV-2, these efforts are primarily centered on identifying nAbs made during natural infections or generating nAbs through animal vaccination approaches. |